#5 - Amber Trivedi, COO at Blue Note Therapeutics
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
#5 - Amber Trivedi, COO at Blue Note Therapeutics
-
Lu par :
-
De :
À propos de ce contenu audio
Welcome to DTx Equals, the show where thought-leaders in digital therapeutics put a stake in the ground about what makes DTx, DTx.
Our Guest Today: Amber Trivedi, COO at Blue Note Therapeutics
What you'll get out of this episode:
- What is a formative event in your life or career that influenced your path into DTx?
- DTx equals what? What is the most defining issue of DTx today?
- How much of the problems with DTx getting reimbursment are around pricing? Do you think prices are being set too high, or do you think healthcare needs to readjust?
- Are there places where healthcare can be disentangled from a human provider?
- Where do you feel non-human DTx models really shine?
- In your wildness dreams, what is something DTx will be able to do in the future that it can’t do today?
To learn more about Amber Trivedi and Blue Note Therapeutics please use the links below:
- Amber's LinkedIn - Blue Note Therapeutics LinkedIn - Blue Note Therapeutics Website
Also, be sure to follow DTx Equals on our social channels:
- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment
